Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2017 19:46 ET | Source: Prima BioMed Ltd

Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston

SYDNEY, AUSTRALIA--(Marketwired - Mar 14, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the second cohort comprising six patients has now been...
February 28, 2017 19:30 ET | Source: PRIMA BIOMED LTD

USA Patent Grants for IMP321 in Cancer

SYDNEY, AUSTRALIA--(Marketwired - Feb 28, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 9,579,382 entitled "Use of Recombinant...
February 24, 2017 02:13 ET | Source: PRIMA BIOMED LTD

First Half 2017 Operational Update

SYDNEY, AUSTRALIA--(Marketwired - Feb 24, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Highlights Positive recruitment rates for TACTI-mel and AIPAC...
February 12, 2017 20:50 ET | Source: Prima BioMed Ltd

Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government

SYDNEY, AUSTRALIA--(Marketwired - Feb 12, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), is pleased to announce that its French subsidiary, Immutep S.A.S., has...
January 22, 2017 19:00 ET | Source: Prima BioMed Ltd

Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

SYDNEY, AUSTRALIA--(Marketwired - Jan 22, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the submission titled "TACTI-mel, Two ACTive Immunotherapies...
January 19, 2017 18:07 ET | Source: PRIMA BIOMED LTD

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

SYDNEY, AUSTRALIA--(Marketwired - Jan 19, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced the first patient has been dosed as part of the enlarged...
January 18, 2017 02:02 ET | Source: PRIMA BIOMED LTD

Prima BioMed to Maintain NASDAQ Listing

SYDNEY, AUSTRALIA--(Marketwired - Jan 18, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock...
January 11, 2017 18:41 ET | Source: PRIMA BIOMED LTD

Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial

SYDNEY, AUSTRALIA--(Marketwired - Jan 11, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced that the first patient has been dosed for the second cohort...
January 05, 2017 02:48 ET | Source: Prima BioMed Ltd

Prima BioMed Enters New Material Transfer Agreement With CYTLIMIC

SYDNEY, AUSTRALIA--(Marketwired - Jan 5, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, today announced that it has entered into a new collaboration agreement...
January 02, 2017 18:37 ET | Source: Prima BioMed Ltd

Prima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody

SYDNEY, AUSTRALIA--(Marketwired - Jan 2, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces that it has developed a new early stage product candidate, a...